Application and current status of EBV antibodies in EBV-related diseases

<p indent="0mm">Epstein-Barr virus (EBV), as the earliest discovered oncogenic virus, is closely related to the pathogenesis of nasopharyngeal carcinoma, gastric cancer and lymphoma. Although EBV has been studied for <sc>60 years</sc> since its discovery in 1964, the mechanism of primary infection, chronic infection and reactivation caused by a variety of severe non-neoplastic diseases, malignant tumors and autoimmune diseases is far from clear. In this review, we summarize the clinical application and research progress of EBV antibodies in EBV-related diseases, and discuss the characteristics of various EBV-related diseases and the challenges of early diagnosis. The main point is to provide theoretical support for the standardized application of EBV antibodies and to help clarify the research directions and application prospects of EBV antibodies.